Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12830195 | 1.00 | MTOR (0.61) | MTORALOX5GAALIMK2KDM4E | |
| SCHEMBL12269652 | 1.00 | MTOR (0.61) | MTORALOX5GAALIMK2KDM4E | |
| Benzene SCHEMBL28986126 | 0.85 | MTOR (0.62) | MTORALOX5GAALIMK2KDM4E | |
| SCHEMBL1520362 | 0.85 | MTOR (0.62) | MTORALOX5GAALIMK2KDM4E | |
| SCHEMBL26638352 | 0.83 | MTOR (0.61) | MTORALOX5GAALIMK2KDM4E | |
| SCHEMBL12783364 | 0.82 | MTOR (0.59) | MTORALOX5GAALIMK2KDM4E | |
| SCHEMBL20901376 | 0.82 | MTOR (0.59) | MTORALOX5GAALIMK2KDM4E | |
| SCHEMBL14768578 | 0.82 | MTOR (0.59) | MTORALOX5GAALIMK2KDM4E | |
| SCHEMBL19481465 | 0.82 | MTOR (0.59) | MTORALOX5GAALIMK2KDM4E | |
| SCHEMBL27892955 | 0.82 | ALOX5 (0.67) | MTORALOX5GAALIMK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2005092841-A1 | COMPOUNDS HAVING BETA-AGONIST ACTIVITY | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | MTOR 995/4885ALOX5 4287/4885GAA 2982/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | MTOR 1667/4885ALOX5 3972/4885GAA 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.